



# SZABO SCANDIC

Part of Europa Biosite

## Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!  
See the following pages for more information!



### Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

### Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

### SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7

[mail@szabo-scandic.com](mailto:mail@szabo-scandic.com)

[www.szabo-scandic.com](http://www.szabo-scandic.com)

[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic) 

## Topsalysin

Cat. No.:	HY-P99554
CAS No.:	917121-25-6
Target:	Others
Pathway:	Others
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.

### BIOLOGICAL ACTIVITY

<b>Description</b>	Topsalysin is a PSA-activated protoxin, a pore-forming protein (synthetic proaerolysin) fusion protein with human prostate-specific antigen. Topsalysin has tumor suppression effect in mice modle <sup>[1]</sup> .	
<b>In Vitro</b>	Topsalysin (19 pM-10 nM; 48 h) shows prostate-specific antigen (PSA)-dependent toxicity against LNCaP, PC3, DU145, and TSU cells <sup>[1]</sup> . MCE has not independently confirmed the accuracy of these methods. They are for reference only.	
<b>In Vivo</b>	Topsalysin (intratumor injection; 1-10 µg/mouse; single dose) inhibits tumor growth in mice bearing <sup>[1]</sup> . Topsalysin (0.35, 4.1, 25.8 µg/kg, 25 µL; i.p.; single dose) could kill up to 50% of cells in the injected site of cynomolgus monkey prostate glands <sup>[1]</sup> . MCE has not independently confirmed the accuracy of these methods. They are for reference only.	
	Animal Model:	Nude mice (6-week-old) subcutaneously bearing tumors <sup>[1]</sup>
	Dosage:	0, 1, 5, and 10 µg
	Administration:	Intratumor injection; single dose; measured tumor sizes at first day and twice weekly for 28 days
	Result:	Showed prostate-specific antigen (PSA)-dependent toxicity in mice.

### REFERENCES

[1]. Williams SA, et al. A prostate-specific antigen-activated channel-forming toxin as therapy for prostatic disease. J Natl Cancer Inst. 2007 Mar 7;99(5):376-85.

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA